The following are the requirements for the medical certification of aircrew, including guidance material issued by the UK CAA Medical Department in relation to the Oncology.
(a) Applicants shall have no established primary or secondary malignant disease likely to interfere with the safe exercise of the privileges of the applicable licence(s).
(b) After treatment for malignant disease, applicants shall undergo satisfactory oncological evaluation before a fit assessment can be made. Class 1 applicants shall be referred to the licensing authority. Fitness of class 2 applicants shall be assessed in consultation with the licensing authority.
(c) Applicants with an established history or clinical diagnosis of intracerebral malignant tumour shall be assessed as unfit
(a) Applicants who underwent treatment for malignant disease may be assessed as fit by the licensing authority if:
(1) there is no evidence of residual malignant disease after treatment;
(2) time appropriate to the type of tumour has elapsed since the end of treatment;
(3) the risk of inflight incapacitation from a recurrence or metastasis is sufficiently low;
(4) there is no evidence of short or long-term sequelae from treatment. Special attention should be paid to applicants who have received anthracycline chemotherapy;
(5) satisfactory oncology follow-up reports are provided to the licensing authority.
(b) A multi-pilot limitation should be applied as appropriate.
(c) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is regular follow-up.
On reporting a diagnosis of malignancy, applicants should be assessed as unfit.
Recertification can be considered following receipt of a satisfactory specialist report with the information in the
15 point Oncology Request table (PDF).
Note 1: All Class 1 applicants shall be referred to the AMS.
1. Recertification a minimum of 6 weeks after the last dose of chemotherapy, subject to satisfactory blood tests results (FBC, U&Es, LFTs, relevant tumour markers as a minimum).
a) Applicants may be assessed as fit after treatment for malignant disease if:
(3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low;
(4) there is no evidence of short or long-term sequelae from treatment that may adversely affect flight safety;
(5) special attention is paid to applicants who have received anthracycline chemotherapy;
(6) arrangements for an oncological follow-up have been made for an appropriate period of time.
(b) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is a regular follow-up.
2. If any complications from treatment, need full recovery. If unresolved, may require appropriate specialist assessment, e.g. neuropathy may require a specialist neurology assessment.
3. Class 1 pilots who have had anthracycline (e.g. doxorubicin, adriamycin, daunorubicin) require cardiological assessment in accordance with the
anthracycline (PDF) flow chart.
1. Recertification a minimum of 4 weeks after the last dose of radiotherapy.
2. If any complications from treatment, need full recovery. If unresolved, appropriate specialist assessment required e.g. radiation pneumonitis/pulmonary fibrosis requires a specialist respiratory assessment.
As a guide, minimum post-operative grounding periods:
e.g. skin lesion
e.g. prostatectomy (TURP)
Metastatic disease is disqualifying for Class 1 and Class 2 certification.
In exceptional cases, Class 2 OSL may be considered by the AMS only.
Incapacitation risks are based on:
1) Risk of a recurrence
2) Site of the recurrence
3) Risk of a recurrence at that site leading to an
Oncology Certification Charts (PDF) have been developed based on these medical incapacitation risks:
2-5% per annum Class 2 OSL
≤ 1% per annum Class 1 OML & Class
0.1% per annum Class 1 Unrestricted
Oncology Certification Charts (PDF) exist for these tumour types:
Testicular germ cell tumour
Renal cell carcinoma
Non-small cell lung cancer
All Class 1 lymphoid malignancies must be referred to the CAA.
The above guidance is also available in Ernsting’s Textbook of Aviation Medicine 4th Edition, Chapter 44, Malignant Disease.
UK CAA Guidance on certification after
Prostate Cancer (PDF)
We are now recruiting an airspace specialist to help answer general enquiries about UK airspace. Experience from wi… https://t.co/8I4i0GwYc2
Airspace restrictions will be in place to protect RAF100 flypast https://t.co/pr2tCoWAzz 10 July. Find out more… https://t.co/KJ1kr3fghx
Visit us at @aeroexpo and pick up our latest Listening Squawk card - it lists all airport codes & frequencies. Keep… https://t.co/2GrfAER0Ug
8 days ago
Read all @UK_CAA
CAA launches investigation into airspace infringement
22 June, 2018
Airspace restrictions announced for Royal Air Force 100 flypast
21 June, 2018
CAA increases operational scope of GA Permit aircraft
12 June, 2018
Read all News
Sharing the cost of recreational flying
4 May, 2018
Planning your next holiday abroad?
10 April, 2018
‘Share the Air’ gets off to a flying start
1 December, 2017
Read All Blogs